Immunotherapeutics
- 1st Edition, Volume 129 - March 11, 2022
- Imprint: Academic Press
- Editor: Rossen Donev
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 9 2 2 7 - 5
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 9 2 2 8 - 2
Immunotherapeutics, Volume 129 in the Advances in Protein Chemistry and Structural Biology series highlights new advances in the field, with this new volume presenting in… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteImmunotherapeutics, Volume 129 in the Advances in Protein Chemistry and Structural Biology series highlights new advances in the field, with this new volume presenting interesting chapters on a variety of topics, including Vaccines for the prophylaxis and treatment of HPV, Lung-targeted RNA-based therapeutics, Clostridium difficile: Current overview and future perspectives, Antivenoms for treatment of snake bites, Natural killer cell-based strategies for immunotherapy of cancer, Immunological insights of selectins in human disease mechanism, Current update, challenges, and future aspects of immunotherapeutics in non-small cell lung cancer, In silico interaction analysis of NEMO binding domain peptide on the NFkB protein, and much more.
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in the Advances in Protein Chemistry and Structural Biology series
- Updated release includes the latest information on Immunotherapeutics
Protein chemists, molecular cell biologists, immunologists, structural biologists, computational biochemists, medical doctors, pharmacologists and other researchers working in the field of transport proteins and drug design. Articles published here would also be of a considerable benefit to medical, biology and pharmacology students specializing in this field
- Cover
- Title page
- Table of Contents
- Copyright
- Contributors
- Chapter One: In silico tools and databases for designing cancer immunotherapy
- Abstract
- 1: Introduction
- 2: Cancer associated genomic data
- 3: Immunological database
- 4: Analysis of genomic profiles
- 5: Prediction of cancer biomarkers
- 6: Identification of vaccine candidates
- 7: Important pipelines
- 8: Cancer-specific immunotherapy
- 9: Miscellaneous
- 10: Discussion and conclusion
- Acknowledgments
- References
- Chapter Two: Immunotherapeutic approaches for HPV-caused cervical cancer
- Abstract
- 1: Introduction
- 2: HPV
- 3: Vaccines
- 4: HPV therapeutic vaccines
- 5: Conclusion
- References
- Chapter Three: Natural killer cell-based strategies for immunotherapy of cancer
- Abstract
- 1: Natural killer cells origin and functions
- 2: NK cell recognition in health and disease
- 3: NK cells as a tool of cancer immunotherapy
- 4: NK cell-based immunotherapeutics
- 5: Concluding remarks
- Acknowledgments
- References
- Chapter Four: Noncoding RNAs as novel immunotherapeutic tools against cancer
- Abstract
- 1: Introduction
- 2: Immunotherapy in human diseases
- 3: Immunotherapy in cancer
- 4: Noncoding RNAs in cancer
- 5: ncRNAs in the regulation of immune checkpoint proteins
- 6: Noncoding RNAs as potential targets for cancer immunotherapy
- 7: Challenges of ncRNA based immunotherapeutics
- 8: Future perspectives
- References
- Chapter Five: Immunological insights of selectins in human disease mechanism
- Abstract
- 1: Introduction
- 2: Adhesion mechanism of leucocytes
- 3: Carbohydrate recognition by selectins
- 4: Structure of selectin
- 5: Selectin's immunological role
- 6: Interaction of selectins with their ligands
- 7: Selectin ligands
- 8: Disease mechanism through selectin signaling
- 9: Selectin as drug target
- 10: Selectins for drug delivery
- 11: Conclusion and future prospects
- References
- Chapter Six: CoVaccine HT™ adjuvant is superior to Freund's in eliciting ovine polyclonal antibodies against human tumor necrosis factor-alpha
- Abstract
- 1: Introduction
- 2: Materials and methods
- 3: Results
- 4: Discussion
- References
- Chapter Seven: Clostridioides difficile: Current overview and future perspectives
- Abstract
- 1: Introduction
- 2: The bacterium
- 3: C. difficile toxins
- 4: Symptoms and diagnosis
- 5: The severity of disease
- 6: Epidemiology
- 7: Pathogenesis
- 8: Prevention
- 9: Current treatment strategies
- 10: Future directions
- 11: Summary and outlook
- References
- Chapter Eight: A computational model revealing the immune-related hub genes and key pathways involved in rheumatoid arthritis (RA)
- Abstract
- 1: Introduction
- 2: Methods
- 3: Results
- 4: Discussion
- 5: Conclusion
- References
- Chapter Nine: Understanding the activating mechanism of the immune system against COVID-19 by Traditional Indian Medicine: Network pharmacology approach
- Abstract
- 1: Introduction
- 2: Materials and methods
- 3: Results and discussions
- 4: Discussion
- 5: Conclusion
- References
- Chapter Ten: Immunotherapeutic interventions in Parkinson's disease: Focus on α-Synuclein
- Abstract
- 1: Introduction
- 2: Parkinson's disease: An overview
- 3: Parkinson's disease and the immune system
- 4: α-Synuclein in Parkinson's disease: Deciphering the cascade of proteotoxic pathways
- 5: Immunotherapeutic strategies in Parkinson's disease
- 6: Conclusion
- References
- Chapter Eleven: Antivenom: An immunotherapy for the treatment of snakebite envenoming in sub-Saharan Africa
- Abstract
- 1: Snakebite envenoming
- 2: Snake venom: Overview
- 3: Antivenom
- 4: Conclusion
- Authors' contribution
- References
- Edition: 1
- Volume: 129
- Published: March 11, 2022
- Imprint: Academic Press
- No. of pages: 492
- Language: English
- Hardback ISBN: 9780323992275
- eBook ISBN: 9780323992282
RD
Rossen Donev
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.
Affiliations and expertise
Head of Research, MicroPharm Limited, UKRead Immunotherapeutics on ScienceDirect